Marvel Biosciences Corp MRVL
TSXV · Canada · Health Technology
CAD 0.1500-0.01 (-3.23%)
Market closed· · CAD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · CAD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Zacks says Marvell shares climbed 28% over the past month as consensus estimates for earnings and revenue moved higher.
The publisher cites Marvell’s growth and Yum’s margins, while pointing to declining sales and profitability at Moderna.
U.S. futures barely moved after a record-setting tech session, while conditional reopening news pushed crude prices down about 2%.